Lucid Dreaming Is a New State of Consciousness, Scientists Find
The awareness of dreaming during a lucid dream is now thought to come from shifts in brain wave activity undergone by several parts of the brain, including the right central lobe, parietal lobe and precuneus.
Lucid dreams were also found to have effects similar to psychedelics like LSD.
Have you ever had a dream in which you realized you were dreaming?
When you become conscious of the fact that you are dreaming, you can take advantage of that knowledge and manipulate the dream. If you want to do something that is physically impossible in the real world, such as flying, you can leap into the air and take flight. Someone who realizes they are trapped in a nightmare can convince themselves to wake up.
The state known as lucid dreaming is an unquestionably surreal one, and it just got even more so. A team of researchers—led by Çağatay Demirel from the Donders Center for Cognitive Neuroimaging at Radboud University Medical Center, the Netherlands—has discovered that lucid dreaming has now been found to be a state of consciousness separate from both wakefulness and REM sleep (the state usually associated with dreams), and is in fact associated with its own unique type of brain activity. They published a study on their findings in the Journal of Neuroscience.
'This research opens the door to a deeper understanding of lucid dreaming as an intricate state of consciousness by pointing to the possibility that conscious experience can arise from within sleep itself,' Demirel said in a press release.
To identify what sets lucid dreaming apart from the rest of sleep, he and his team pulled previous studies—in which brain activity was measured with EEG sensors—together into what is now the most extensive dataset in this field of sleep research. The researchers then compared brain activity patterns for wakefulness, REM sleep, and lucid dreaming to find that that the eerie self-awareness experienced in lucid dreams has a connection to the electrical rhythms in neurons known as brain waves.
Perception and memory processing in the lucid dreaming state were found to be different from non-lucid REM sleep. The consciousness of existing in a dream was associated with with beta waves in the right central lobe (which controls spatial awareness and nonverbal memory) and parietal lobe (which controls the sense of touch and spatial awareness). Beta waves are a type of high-frequency electromagnetic activity in the brain involved in conscious thought processes like solving problems or making decisions. Our consciousness is dominated by beta waves when we are awake.
This might explain why there is so much cognitive control in lucid dreams. Dreamers deep in REM sleep have no sense of control over factors like thoughts, feelings, and behaviors, but those in lucid dreaming states do.
Demirel also linked gamma waves with lucid dreaming. These are the fastest brain waves, which become visible on an EEG at times when the brain is especially alert and focusing on something. When lucid dreaming begins, gamma waves increase in the right precuneus, which is involved in self-referential thinking—thoughts about ourselves and our lives. When we are awake, we often drift into this type of thinking when our minds wander.
Maybe the most mind-bending thing about lucid dreams is that they are, according to the study, similar in the brain to the effects of psychedelic drugs such as LSD and ayahuasca. These types of psychedelic experiences are also associated with the precuneus, whose activity is modified when waking imagery is seen despite having closed eyes (something usually only experienced with psychedelics). Interestingly, however, lucid dreams may even go a few experiential steps past psychedelics. 'While psychedelics often lead to a dissolution of ego and decreased self-referential processing […] lucid dreams may actually harness elements of self-awareness and control,' Demirel and his team said in the study.
So if you're capable of lucid dreaming, you're in for an awesome trip.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
29-07-2025
- CNN
Federal officials push to restrict kratom-derived opioid 7-OH
Federal officials promised on Tuesday to crack down on a potent semisynthetic opioid found in convenience store gummies, drinks and dietary supplements by putting the substance in the most restricted class of drugs. The action by the US Department of Health and Human Services and the Justice Department targets a compound called 7-hydroxymitragynine, or 7-OH, that is drawn from the opioid-like herb kratom. Taken in small doses, kratom and that component can act as a stimulant, and some people use it to manage opioid withdrawal symptoms. Although 7-OH occurs naturally in 'trace amounts' in kratom, some consumer products on the market have concentrated amounts of 7-OH, the US Food and Drug Administration has said. 'We are not targeting the kratom leaf or ground-up kratom. We are targeting the concentrated synthetic byproduct that is an opioid,' FDA Commissioner Dr. Marty Makary said Tuesday during an HHS event. Federal health agencies have seen a 'disturbing rise in reports of overdoses, poisonings and emergency room visits' with products containing 7-OH, HHS Deputy Secretary Jim O'Neill said. The substance carries risks of addiction but is often sold without dosage controls or warnings, he added. Yet there are 'terrible statistics' on how many people have actually overdosed from 7-OH products, Makary said, because few doctors are familiar with the substance. Health officials are also working on education campaigns and research on 7-OH, he said. Makary said the FDA is recommending that 7-OH be listed as Schedule I, the most restrictive class of controlled substances. The government defines drugs in that class — including heroin, cocaine, cannabis, LSD and psilocybin — as having no currently accepted medical use and a high risk of addiction. Other opioids, such as fentanyl and morphine, are in a lower schedule because they are used medically. It is unclear where health officials would recommend that the Drug Enforcement Administration place leaf or ground kratom, which contain less 7-OH than synthetic products but are also virtually unregulated. Asked about the potential for future natural kratom regulations, Makary said some physicians have expressed concerns about its risks and addiction potential. But, he added, 'We have to prioritize what we work on, so we are going after the killer first, which is the synthetic, concentrated kratom, and then we can look into that other question. But we think it's night and day in terms of the public health risk.' On July 15, the FDA sent warning letters to seven companies marketing 7-OH products including gummies, tablets and drink mixes. The agency reiterated in those letters that it is illegal to add the substance to any dietary supplements or food products — though that has proved difficult to regulate, as kratom regularly appears in products at smoke shops and gas stations. Several former health officials from the first Trump administration have publicly urged the government to step up regulation of kratom and 7-OH in particular. Former US Centers for Disease Control and Prevention Director Dr. Robert Redfield penned a June op-ed in The Hill arguing that health agencies would not need to 'reinvent the wheel' but adopt a standard set forth in recent legislation. 'Natural kratom leaf, when used as it has been for centuries, presents a markedly different risk profile than the synthetic products flooding American markets,' Redfield wrote. But that leaves the open question of how to regulate natural kratom. In 2018, the FDA declared the herb, derived from an Asian evergreen tree, an opioid. 'There is no evidence to indicate that kratom is safe or effective for any medical use,' then-FDA Commissioner Dr. Scott Gottlieb said in a February 2018 statement. 'And claiming that kratom is benign because it's 'just a plant' is shortsighted and dangerous.' That statement is no longer available on the FDA website. The agency now states that 'until the agency scientists can evaluate the safety and effectiveness of kratom (or its components) in the treatment of any medical conditions, FDA will continue to warn the public against the use of kratom for medical treatment.' Melody Woolf, an advocate for people with chronic pain, championed the benefits of natural kratom at Tuesday's HHS event. 'I was so grateful I found a botanical called kratom,' she said. 'It was kratom only, the powdered leaf, that saved my life. And now I'm seeing something very dangerous happen: 7-OH is being sold over the counter.' The Holistic Alternative Recovery Trust, an advocacy organization focused on opioid addiction, pushed back on the claims after Tuesday's event and noted that officials weren't able to point to any deaths attributed to 7-OH. 'Since today's announcement did not reference any concrete public health data, we can only conclude that instead of public health being paramount, other interests may be driving policy decisions,' Jeff Smith, the group's national policy director, said in a statement. 'The FDA needs to hear from researchers, toxicologists, and addiction science experts — and from the American people. Cutting off access helps no one, but it will hurt many.'
The Hill
29-07-2025
- The Hill
FDA recommends concentrated Kratom be scheduled as illicit substance
The Trump administration is recommending that a compound called 7-OH be scheduled as an illicit drug, Food and Drug Administration Commissioner Marty Makary announced Tuesday. The compound is a concentrated by-product of the Kratom plant whose ground leaves are sold as a dietary supplement to boost energy or provide pain relief. FDA officials said the substance has a 'high risk of addiction' and abuse in concentrated form because of its ability to bind to opioid receptors in the brain. Makary said the agency is urging the Drug Enforcement Agency to classify 7-OH as a Schedule 1 substance, placing it on list of drugs that include heroin, lysergic acid diethylamide (LSD) and ecstasy. 'We have a history in public health of being asleep at the wheel,' Makary said. 'Public health is supposed to prevent disasters, not just clean them up after they've killed thousands and thousands of people.' The American Kratom Association (AKA), a trade group representing the industry, applauded the recommendation to classify 7-OH as a Schedule 1 substance. 'This bold step is a critical milestone in protecting public health and consumer safety from dangerous synthetic products that masquerade as natural kratom,' the AKA said in a statement. A spokesperson for the group said that the FDA's decision shines a light on a 'massive and growing' problem in the kratom marketplace. Earlier this month, the FDA sent warning letters to seven companies regarding allegations that they are illegally marketing 7-OH products as dietary supplements or as a product that can relieve pain or manage anxiety. Department of Health and Human Services officials said during a Tuesday press conference that they have seen a 'disturbing' rise in reports of poisonings and emergency room visits linked to products containing 7-OH which can be found in tablets, gummies, mixed drinks or shots. But officials did not point to data on the scale of the rise in adverse health events. These products are often sold online or in convenience stores, gas stations and vape shops, officials said, with no 'quality control, no dosage control and no warnings.' 'This is a recipe for a public health disaster,' said Jim O'Neil, deputy secretary at the Department of Health and Human Services. 'Young people, veterans and people who suffer from chronic pain or addiction are being misled into thinking that these are safe alternatives. They're not.' Kratom has gained popularity as an alternative pain reliever amid the country's opioid epidemic with some studies suggesting that up to 15 million Americans have use it to treat chronic pain or opioid withdrawal symptoms. In small doses, Kratom can act as a stimulant but can also cause an 'opioid-like' drowsiness and euphoria, experts say. Concentrated Kratom or highly potent Kratom products can cause harmful side effects like nausea, vomiting and even seizures. Tuesday's announcement is the Trump administration's effort to prevent another 'wave of the opioid epidemic' from blindsiding the country, Makaray said. 'There's a lot we don't know. This may be the calm before the storm,' he said. 'It may be the tip of the iceberg, but let's be aggressive and proactive.' The DEA previously announced it would schedule kratom compounds as controlled substances in 2016 but opted not to after receiving intense pushback. Makary stressed that the Trump administration is targeting synthetic, concentrated kratom when asked by a reporter if officials were prepared to deal with similar pushback again.
Boston Globe
29-07-2025
- Boston Globe
US health officials crack down on kratom-related products after complaints from supplement industry
The FDA action 'is not focused on natural kratom leaf products,' according to a statement Tuesday by the U.S. Department of Health and Human Services. Advertisement The agency said it was releasing a report to educate about the risks of '7-OH and its distinction from the kratom plant leaf.' Regulators are also recommending that the ingredient be placed on the federal government's most restrictive list of illegal drugs, which includes LSD and heroin. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up '7-OH is an opioid that can be more potent than morphine,' said FDA Commissioner Marty Makary. 'We need regulation and public education to prevent another wave of the opioid epidemic.' The agency's recommendation will be reviewed by the Drug Enforcement Administration, which sets federal rules for high-risk drugs including prescription medicines and illicit substances. A federal ban wouldn't take effect until the agency drafts and finalizes new rules governing the ingredient. Federal regulators have been scrutinizing kratom for about a decade after reports of addiction, injury and overdose. But users and distributors have long opposed efforts to regulate it, saying kratom could be a safer alternative to opioid painkillers that sparked the ongoing drug addiction epidemic. Advertisement Last month, the FDA issued warning letters to seven companies selling drinks, gummies and powders infused with 7-OH. Regulators said the products violated FDA rules because they have not been evaluated for safety and, in some cases, claimed to treat medical conditions, including pain, arthritis and anxiety. Supplement executives quickly applauded the move. The FDA 'demonstrated the exact kind of data-driven, proactive regulatory excellence needed to safeguard unwitting consumers across the U.S.,' said Ryan Niddel of Diversified Botanics, a Utah-based company that sells kratom supplements. An industry group, the American Kratom Association, has lobbied Congress for years against restrictions on the plant. Legislation supported by the group would prohibit the FDA from regulating kratom more strictly than food and dietary supplements Nearly a decade ago, the federal government came close to banning the substance. In 2016, the DEA announced plans to add kratom to the government's most restrictive schedule 1, reserved for drugs that have no medial use and a high potential for abuse. But the plan stalled after a flood of public complaints, including a letter signed by more than 60 members of Congress. The FDA then began studying the ingredient, concluding in 2018 that kratom contains many of the same chemicals as opioids, the addictive class of drugs that includes painkillers like OxyContin as well as heroin and fentanyl. Since then, FDA regulators have continued to issue warnings about cases of injury, addiction and death with kratom supplements, which are usually sold in capsules or powders. Advertisement In recent months, the FDA has also issued warnings on other unapproved drugs sold as supplements or energy drinks, including the antidepressant tianeptine
